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Concurrent Session 1 Management of Hepatitis B
I-14 Treatment of hepatitis B virus
M. Omata*. Department of Gastroenterology, University of
Tokyo, Japan
HBV was discovered in 1964 and HBV suppression by
treatment started in late 1970 by Dr. Greenberg using
Interferon. However, until 1998 when Dr. CL Lai reported
one year experience of Lamivudine in N Engl J Med, the
treatment of HBV has not become common practice. That
time, I wrote critical comment on this article by Editorial
in N Engl J Med (1998; 339: 114 5). Because the majority of
the patients treated had infection more than thirty years or
sometimes even ﬁfty years. And only one year suppression
is not obviously sufﬁcient to change the natural course of
HBV infection. Subsequently, very high resistance rate was
noted in the Lamivudine treatment and long-term efﬁcacy
was blurred.
And now, experiences of three to ﬁve years of drug use
were gathered and several drugs seem so far very safe and
potential suppressor of HBV replication for long time. Now
the question is raised how long it can continue to suppress
HBV before the emergence of HBV resistant mutant. In my
talk, I will compare the potency and durability of several
drugs and emergency of resistant strains. In addition, I
will address the validations of new APASL guideline by our
own patients’ data and on the Japanese experiences of
the improvement of liver history, treated by nucleoside
analogues for 3 years. We know envision the use of these
drugs for longer than ﬁve years. I personally feel if these
drugs can suppress longer than ten years, probably the
natural course of HBV infection could be drastically changed
in the majority of HBV carriers.
I-15 From the pathogenesis to the therapeutic strategy
of chronic hepatitis B infection
G.Q. Wang*. Department of Infectious Diseases & Center
for Liver Diseases, Peking University First Hospital, Beijing
100034, China
Chronic HBV infection is a severe public health problem in
the world, especially in China and Asia-Paciﬁc Area. Although
some new drugs developed in the treatment of chronic
hepatitis B, such as pegylated interferon, lamivudine,
adefovir, entecavir and telbivudine, not all the patients
beneﬁt from them, especially the sustain response is not
satisﬁed.
There are two main reasons for the HBV infection as an
intractable disease. One is the HBV cccDNA, the template
for the replication of virus, that no drugs have worked
on it. Another is the immune tolerance or dysfunction of
the host immune system on HBV. The ﬁnal elimination of
the HBV cccDNA depends upon the immune system, that
is, the viral speciﬁc cytotoxic T lymphocyte (CTL) and
cytokines contribute the sustain viral inhibition by inducing
the apoptosis of the viral infected hepatocytes, and the
exhaustion of the cccDNA reservoir by sustain inhibition of
the viral replication. So, immune modulation treatment that
can provoke the immune system will play a very important
role in the control of HBV infection.
As the sustain HBV inhibition rely on the immune system,
the immune modulatory agents should be considered as
the main therapeutic strategy of chronic HBV infection,
unfortunately, only interferon a including pegylated
interferon will be used in the young patients with low
level HBVDNA and elevated ALT, and Thymosin a1 can be
one of candidate as a immunomodulatory agent. As the
nucleos(t)ide acid has a strong potency of inhibiting the virus
but no immunomodulatory effect, the combination with two
type agents will be a potential strategy in the future. The
development of new agents with immunomodulatory effect
may change the outcome of chronic hepatitis B patients,
but there is a long way to go.
Concurrent Session 2 Bacterial infection
I-16 Prevalence of dupA of Helicobacter pylori strains
isolated from Shanghai patients and its clinical
implications
H. Lu*. Shanghai Renji Hospital afﬁliated to Shanghai Jiao
Tong University School of Medicine, Shanghai Institution of
Digestive Disease, Shanghai, China
Aims: To determine the prevalence of duodenal ulcer
promoting (dupA) gene of Helicobacter pylori in patients
with various gastroduodenal diseases in Shanghai and to
explore the association between the gene and other
putative virulence factors.
Methods: H. pylori were isolated from gastric biopsies of
patients with chronic gastritis, duodenal ulcer (DU), gastric
ulcer (GU), or non-cardia gastric carcinoma. The dupA,
cagA, vacA, iceA and babA2 genotypes were determined by
polymerase chain reaction. Histological features of gastric
mucosal biopsy specimens were graded based on the scoring
system proposed by the updated Sydney system.
Results: Isolates from 360 patients including 133 with
chronic gastritis, 101 with DU, 47 with GU, and 79 with
non-cardia gastric carcinoma were examined. The dupA
gene was detected in 35.3% (127/360) and the prevalence
DU patients was signiﬁcantly greater than that in gastric
cancer or GU patients (45.5% vs. 24.1% and 23.4%,
P < 0.05). Patients infected with dupA-positive strains had
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higher scores for chronic inﬂammation compared to those
with dupA-negative strains (2.36 vs. 2.24, p = 0.058). The
presence of dupA was not associated with the cagA, vacA,
iceA or babA 2 genotypes.
Conclusions: In Shanghai the prevalence of dupA gene was
highest in DU and inversely related to GU and gastric cancer
both which are associated with corpus atrophy.
I-17 Antimicrobial susceptibility testing through
EUCAST
G. Kahlmeter1,2 *. 1Clinical Microbiology, Central Hospital,
Va¨xjo¨, Sweden, 2The European Committee on Antimicrobial
Susceptibility Testing (EUCAST), NONE
In order to categorise a bacterium as sensitive to
an antibiotic, it is necessary to perform a phenotypic
antimicrobial susceptibility test. Phenotypic AST systems
need breakpoints to. categorise bacteria S, I or R.
Breakpoints are best determined by breakpoint committees
consisting of experts in the ﬁelds of clinical microbiology
and infectious diseases. Both CLSI (formerly NCCLS
in the USA) and EUCAST (the European Committee
on Antimicrobial Susceptibility Testing) are well known
breakpoint committees. The former is a commercial
enterprise engaging the pharmaceutical industry and
the profession whereas the EUCAST is organised by
the European Centre for Disease Control, the European
Medicines Evaluation Agency and the European Society for
Clinical Microbiology and Infectious Diseases. EUCAST has
harmonised breakpoints for Europe and acts as the EMEA
breakpoint committee during the process of approval of
new drugs.
EUCAST breakpoints are currently being introduced in
automated systems for AST. The Phoenix from Becton
Dickinson is already validated with EUCAST breakpoints and
the Vitek2 from BioMerieux is to follow. A disk test based on
Mueller Hinton agar and 108 cfu/mL inoculum is currently
being developed by EUCAST.
New therapeutic traditions, dosage practices, new tools for
setting breakpoints and most importantly new resistance
mechanisms necessitates an evolutionary process for clinical
breakpoints. EUCAST has an active process for reviewing and
revising breakpoints.
EUCAST offers free documents on breakpoints, methods
and interpretive criteria on its website (www.eucast.org)
which also displays MIC- (and eventually zone diameter-)
distributions of wild type bacteria on the website. These
can be used for calibration of methods.
I-18 Laribacter hongkongensis: From discovery to
complete genome sequence
P.C.Y. Woo. Department of Microbiology, The University of
Hong Kong, Hong Kong, China
Despite extensive investigations, a microbiological cause
cannot be found in about half of the patients with infectious
disease. Throughout the years, scientists have spent
tremendous efforts in looking for microorganisms associated
with these “unexplained infectious disease syndromes”. In
2001, we discovered Laribacter hongkongensis gen. nov.
sp. nov., a facultative anaerobic, Gram-negative, S-shaped,
urease-positive rod of the Neisseriaceae family, from blood
and empyema thoracis of a patient with alcoholic cirrhosis.
During the past seven years, we have documented that
L. hongkongensis was associated with gastroenteritis and
traveler’s diarrhea and cases were found globally in patients
who resided in or had recent travel histories to countries
in Asia, Europe, America and Africa. We have found that
freshwater ﬁsh is the reservoir and it was also found
in drinking water reservoirs. We have cloned the beta-
lactamase and tetracycline resistance genes and developed
gene deletion and expression systems for L. hongkongensis.
Due to the potential of its clinical importance and
related ecology, important phenotypic characteristics and
phylogenetic position, and the availability of genetic
manipulation systems for downstream experiments, we
sequenced the complete genome of L. hongkongensis, with
the aim of achieving better understanding of its biology,
mechanism of adaptation to different hosts, and virulence
mechanisms.
I-19 Antibiotic resistance in gram-negative pathogens:
Dealing with untreatable infections
P.A. Tambyah*. National University of Singapore,
Singapore
While resistant gram-positive pathogens such as MRSA and
VRE have received a lot of attention especially in the US and
Europe, there have been rising numbers of multi-resistant
and even pan-drug resistant strains of gram-negative bacilli
in particular Pseudomonas and Acinetobacter spp. These
have posed tremendous challenges to the clinicians looking
after patients especially in Asia and Southern Europe. With
limited therapeutic options, a greater focus on prevention
and control has resulted. We are also hampered by a lack of
good data to explain the emergence of these pathogens and
to understand the reasons for their spread to our vulnerable
patients.
I-20 Two stage theory pathogenic mechanism of
Streptococcus suis
J. Xu, H. Zheng, C. Ye, H. Jing. State Key Laboratory
for Infectious Disease Prevention and Control, and
National Institute for Communicable Disease Control and
Prevention, China
Streptococcus suis infections are enzootic in pigs where
sporadic cases occur in humans. Since the ﬁrst human case
was recorded in 1968, only 250 cases have been reported
globally through June 2005. The majority of the cases have
resulted in meningitis often associated with hearing loss.
During the period from July to August 2005, however, an
explosive outbreak of 215 cases of human infection occurred
in Sichuan Province, China. Sixty-one of the 215 (28%)
patients presented an unusual streptococcal toxic shock
like syndrome (STSLS) with high mortality (38 of 61; 62%) in
previously healthy farmers. Both the clinical presentation
and epidemiology features of the Sichuan outbreak had not
previously been observed.
This outbreak was caused by a mutant S. suis named
as sequence type 7 (ST7) using the multi-locus sequence
typing method, the method of choice for addressing
questions related to genotyping for epidemiological studies,
population, and evolutionary biology. The ST7 strain caused
a single case described from Hong Kong in 1996; then it
emerged to cause a small outbreak in Jiangsu in 1998; and
spread to cause the largest ever outbreak with severe shock
in 2005.
It was found that the serum levels of IL-1b, IL-6, IL-8, IL-12,
p70, IFN-g and TNF-a, the inﬂammation cytokines, during
the early phase of the disease were signiﬁcantly elevated in
patients with STSLS compared to those with meningitis only.
And, the serum levels of pro-inﬂammatory cytokines were
signiﬁcantly higher in mice infected with the ST7 strain than
in those infected with either the ST1 or ST25 strains.
Genome comparisons showed the ST1 strain had acquired
132 genomic islands, including 5 pathogenicity islands, and
the “epidemic” strain ST7 had acquired an additional 5
genomic islands. Therefore, We proposed the intermediate
virulent ST25 type evolved to become the highly pathogenic
